Qianhe Zhou

Qianhe Zhou

Company: Foghorn Therapeutics

Job title: Principal Scientist

Seminars:

Live Panel Q&A – Ask the Speakers Your Burning Questions 5:00 pm

Read more

day: Day One

Discovery of FHD-609: A Potent & Selective IV Administered Heterobifunctional Degrader of BRD9 in Phase 1 Clinical Trials 4:10 pm

Introduction to Foghorn Therapeutics and discovery platforms Synovial Sarcoma and rational of degrading BRD9 in Synovial Sarcoma Preclinical in vitro and in vivo data of FHD-609 in Synovial Sarcoma modelsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.